Cracow

• An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting
  2024-511166-36-00 5 2025-06-13 Moderate to Severe Plaque Psoriasis
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants from Approximately 2 Months of Age Recruiting
  2023-507600-32-00 5 2025-05-22 Pneumococcal Immunization
• A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants … Recruiting
  2024-514239-21-00 3 2025-05-21 Spinal Muscular Atrophy
• A Phase I, Open-Label Study of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis (RA) Recruiting
  2024-519114-31-00 3 2025-05-15 Treatment-Refractory Rheumatoid Arthritis
• A Phase 2 Study of AMG 193 in Subjects With MTAP-deleted Advanced NSCLC Recruiting
  2024-514459-14-00 4 2025-04-22 Non-Small Cell Lung Cancer
• A Study to Assess the Effectiveness and Safety of Induction Therapy with RO7790121 in Participants with Moderately to Severely Active Crohn' … Recruiting
  2024-513054-30-00 5 2025-04-16 Moderately to Severely Active Crohn's Disease (CD)
• A dose ranging study to investigate efficacy and safety of subcutaneous TOUR006 compared with placebo in participants 18 to 80 years of age … Recruiting
  2024-514801-69-00 4 2025-04-02 Thyroid Eye Disease
• Efficacy and Safety Study of Once-Daily Extended-Release Levetiracetam in Drug-resistant Focal Onset Seizures Recruiting
  2024-514499-42-00 5 2025-03-12 Refractory Partial Onset Epilepsy
• A clinical trial to learn about the effects of VHB937 in people with amyotrophic lateral sclerosis (ALS) Recruiting
  2024-512536-29-00 4 2025-02-28 Amyotrophic Lateral Sclerosis (ALS)
• An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients w … Recruiting
  2023-507853-13-00 4 2025-02-25 Ulcerative Colitis
• A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis Recruiting
  2024-512126-29-00 5 2025-02-25 Generalized Myasthenia Gravis
• Randomized Phase 3 Trial of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Ade … Recruiting
  2024-513317-12-00 5 2025-02-05 Pancreatic cancer
• Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting
  2023-503188-40-00 5 2025-01-06 Active Ulcerative Colitis or Crohn’s Disease
• Selective Treatment of Oral Povorcitinib in Prurigo Nodularis Study 1 (STOP-PN1) Recruiting
  2024-511879-16-00 5 2024-12-12 Prurigo Nodularis
• Concentration of ofatumumab in the breast milk of lactating women with relapsing forms of multiple sclerosis Recruiting
  2023-505283-11-00 6 2024-12-10 Relapsing forms of Multiple Sclerosis (RMS)
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting
  2024-514135-17-00 5 2024-11-28 Immunoglobulin A Nephropathy
• Efficacy and Safety of a New Formulation of Oral Cladribine Compared with Placebo in Participants with Generalized Myasthenia Gravis (MyCla … Recruiting
  2023-507746-83-00 5 2024-11-27 Generalized Myasthenia Gravis
• A randomized, two-period crossover study to demonstrate the comparability of pharmacokinetics of subcutaneous ianalumab between 2mL auto-inj … Recruiting
  2023-508996-35-00 4 2024-11-18 Rheumatoid Arthritis
• Study BT8009-230 in Subjects with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) Recruiting
  2023-504231-41-01 10 2024-10-02 Locally advanced or metastatic urothelial cancer
• Vitrectomy and subretinal TPA for submacular haemorrhage secondary to wet AMD (TIGER). Recruiting
  2023-504751-28-00 5 2024-09-24 Exudative age-related macular degeneration
• A Trial Investigating Lu AG22515 in Adult Participants With Moderate-to-Severe Thyroid Eye Disease Recruiting
  2023-508693-29-00 3 2024-09-19 Active, moderate-to-severe TED
• Study of GS-1427 in Participants With Moderately to Severely Active UC Recruiting
  2023-508304-38-00 4 2024-09-10 Ulcerative Colitis (UC)
• A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting
  2024-512865-15-00 4 2024-09-03 Generalized Myasthenia Gravis

Showing 121–144 of 1,081 trials